Skip to content
HowShorted

Sarepta Therapeutics, Inc. short interest in 2018

In 2018, Sarepta Therapeutics, Inc.'s disclosed short interest ran from 16.72% of shares outstanding on 12 Jan 2018 to 13.33% on 31 Dec 2018, a change of -3.39 percentage points. The year's high was 16.91% on 15 May 2018 and its low 13.20% on 15 Aug 2018, averaging 14.54% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.09 days on 14 Dec 2018. Full history: Sarepta Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Sarepta Therapeutics, Inc. in 2018

2018 in figures

Start of year
16.72% (12 Jan 2018)
End of year
13.33% (31 Dec 2018)
Change
-3.39 pp
High
16.91% (15 May 2018)
Low
13.20% (15 Aug 2018)
Average
14.54%
Highest days to cover
13.09 (14 Dec 2018)
SEC filings marked
5

Every report in 2018

Sarepta Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201816.72%4.52results (8-K)
31 Jan 201814.15%5.75
15 Feb 201814.32%5.94
28 Feb 201814.23%8.34
15 Mar 201815.82%5.6210-K filed
29 Mar 201815.29%8.44
13 Apr 201815.57%8.22
30 Apr 201815.17%10.74
15 May 201816.91%6.3110-Q filed
31 May 201814.76%8.69
15 Jun 201815.25%6.88
29 Jun 201814.96%2.26
13 Jul 201814.65%11.78
31 Jul 201813.91%8.83
15 Aug 201813.20%8.0610-Q filed
31 Aug 201813.59%11.70
14 Sep 201814.02%8.81
28 Sep 201813.94%9.66
15 Oct 201814.48%5.91
31 Oct 201814.01%8.6310-Q filed
15 Nov 201813.74%6.79
30 Nov 201813.62%11.76
14 Dec 201813.27%13.09
31 Dec 201813.33%8.68

See also: Sarepta Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.